New oral treatment option for rheumatoid arthritis

June 19, 2017, Medical University of Vienna
New oral treatment option for rheumatoid arthritis
Credit: Medical University of Vienna

Patients suffering from rheumatoid arthritis are treated for around six months with the standard anti-rheumatic agent methotrexate, to which many patients respond very well. However, if they do not respond and no remission or at least reduction in the activity of the disease can be achieved, they are given a combined treatment of methotrexate and a biologic agent (frequently an anti-TNF, such as e.g. adalimumab, administered by injection), if risk factors are present. An international research group has now shown that there is another, equally effective oral treatment option: the combination of methotrexate and the chemically synthesised Janus Kinase Inhibitor tofacitinib. The results of the study, for which MedUni Vienna rheumatologist Josef Smolen was senior author, have now been published in The Lancet.

Smolen, head of the Division of Rheumatology at MedUni Vienna and the third most quoted rheumatology expert, and researchers from the USA, Argentina, Australia, the UK and China, were able to demonstrate that the combination of /tofacitinib produced equally effective results as the current standard combination of methotrexate/adalimumab. The latter has to be injected into every two weeks, whereas the new option involves taking two tablets a day – a potential advantage for patients. A total of just over 1,100 volunteers were involved in the study.

Says Smolen: "At the same time we were able to show that monotherapy with tofacitinib does not achieve such good results as combined therapy with methotrexate, even though it is still quite effective."

Tofacitinib as an "enzyme inhibitor"

How does Tofacitinib work? It inhibits particular enzymes (Janus Kinases (JAK)), which are jointly responsible for the inflammatory response in . JAKs carry signals from various inflammatory messenger substances, such as interleukin-6 or interferons, into the cell and are therefore largely responsible for triggering the destructive inflammation that occurs in rheumatoid arthritis. If these enzymes are inhibited, the painful immune response that occurs in this autoimmune disease is suppressed. Tofacitinib, which has already been on the market in the USA for some time now, was recently licensed in the European Union.

Approximately 80,000 Austrians have rheumatoid arthritis

Around 3% of the population have a form of inflammatory rheumatism (hence around 250,000 people in Austria) and around 1% have rheumatoid (approx. 80,000 people in Austria).

Explore further: Rheumatism treatment effective even when the use of biological agents is slightly delayed

More information: Roy Fleischmann et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial, The Lancet (2017). DOI: 10.1016/S0140-6736(17)31618-5

Related Stories

Rheumatism treatment effective even when the use of biological agents is slightly delayed

December 5, 2013
The immediate use of a biological agent associated with more side effects and higher costs in the treatment of rheumatoid arthritis yields no better results than a less aggressive plan with the delayed use of biological agents ...

New effective treatments for psoriatic arthritis patients

June 16, 2017
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference revealed promising data supporting two new drug classes for the treatment of psoriatic arthritis (PsA).

New treatment option for difficult-to-treat rheumatoid arthritis patients

March 2, 2017
Between 3 and 5 percent of the population suffers from a form of inflammatory rheumatism. It affects approximately 250,000 to 400,000 people in Austria. Rheumatoid arthritis is one of the most common and also the most dangerous ...

Scientists improve arthritis treatments: Rheumatism patients can hope for a new therapy

February 14, 2013
Together with colleagues from the international rheumatic diseases research community, scientists of the Charité – Universitätsmedizin Berlin have presented a new therapy approach for the treatment of rheumatoid arthritis ...

Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

Tofacitinib ups rheumatoid arthritis treatment response

August 22, 2013
(HealthDay)—The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. ...

Recommended for you

Scientists find key proteins control risk of osteoarthritis during aging

February 14, 2018
More than 30 million Americans suffer from osteoarthritis making it one of the most common age-related diseases.

Acute treatment suppresses posttraumatic arthritis in ankle injury

February 7, 2018
A University of Iowa study has identified a method for inhibiting the occurrence of an aggressive form of arthritis that frequently develops following a severe traumatic injury. The preclinical work demonstrates the potential ...

Small molecule could make a big difference for arthritis patients

February 7, 2018
Will there come a time when a patient with arthritis can forgo joint replacement surgery in favor of a shot? Keck School of Medicine of USC scientist Denis Evseenko, MD, PhD, has reason to be optimistic.

Study finds bacteria in milk linked to rheumatoid arthritis

January 30, 2018
A strain of bacteria commonly found in milk and beef may be a trigger for developing rheumatoid arthritis in people who are genetically at risk, according to a new study from the University of Central Florida.

Osteoarthritis could be treated as two diseases, scientists reveal

January 10, 2018
Scientists at The University of Manchester have discovered that most people with osteoarthritis can be subdivided into two distinct disease groups, with implications for diagnosis and drug development.

US arthritis prevalence is much higher than current estimates

November 27, 2017
New research indicates that the prevalence of arthritis in the United States has been substantially underestimated, especially among adults

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.